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Elevated Troponin
and Aortic Valve Disease
I read with great interest the recent paper by Newby et al. (1) on
interpretation of troponin elevations. The investigators discuss a
considerable variety of disease states but leave out an important
cause of troponin elevation: aortic valve disease.
A decade ago, aortic valve disease patients were shown to
frequently have elevated troponin I values (2). This finding was
subsequently confirmed by Kupari et al. (3). Aortic valve disease
may manifest itself through chest pain, and may be one of thecauses for a false diagnosis of myocardial infarction. It is important
to point out that, on the whole, the syndrome of chest pain,
elevated troponin levels, but no significant coronary artery disease,
is not a benign condition (4).
Apart from diagnostic considerations, troponin may also have
prognostic significance in this context. Rosjo et al. (5) showed that
elevated troponin levels had prognostic implications in patients
with aortic valvular stenosis. Solberg et al. (6) studied symptomatic
aortic stenosis patients and found that high-sensitive troponin T
and N-terminal–brain natriuretic peptide predicted outcomes.
Troponin may therefore be an important biomarker in the
evaluation of patients with aortic valve disease.
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Troponins Should Be
Confirmed With CK-MB
in Atypical Presentations
Newby et al. (1) provide a timely reminder of the importance of
pre-test probability in the interpretation of any diagnostic test
result, particularly the cardiac troponin. Their expert consensus
document makes clear that sensitive troponin assays are not
specific for myocardial infarction (MI) or acute coronary syndrome
(ACS), rather only for myonecrosis that may occur in multiple
acute or chronic conditions.
Their admonition to order troponin “only if clinically indi-
cated,” however, is likely to fall on deaf ears. Physicians order
troponin for as many as 50% of all admitted patients (2) because
symptoms and electrocardiography are often nondiagnostic, and
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April 2, 2013:1461–8missed MIs represent a major cause of legal liability. Similarly, the
advice to interpret an elevated troponin level in the clinical context
is wise, yet may have a limited effect—estimates of pre-test
probability have a high interobserver variability (3). Physicians
often do not make formal quantitative calculations in practice (4)
and make errors when they do (5).
Troponins, as currently used, have an excellent negative predic-
tive value, but poor positive predictive value. The absolute value of
troponin and the degree of increase on sequential testing are
helpful in diagnosing acute MI, but may be less helpful in
confirming thrombotic ACS as the cause. We have observed cases
of acute troponin I increases as great as 10 ng/ml with stroke, diabetic
ketoacidosis, and heart failure. As the key therapeutic decision to
provide antithrombotics or urgent revascularization usually occurs on
presentation, and such therapies can only benefit patients with
significant ACS, practicing clinicians need a second confirmatory test
for ACS. Such a test should be less severely affected by sepsis,
tachyarrhythmia, hypotension, renal failure, chronic coronary disease,
demand ischemia, heart failure, or cardiomyopathy, even if it is
insensitive to small amounts of myonecrosis. That test, arguably, is the
creatine kinase–myocardial band and index.
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Reply
The American College of Cardiology Foundation (ACCF) wel-
comes letters to inform its ongoing work and encourages such
correspondence about its clinical policy statements. Because the
ACCF document development process is rigorous and involves
several layers of review by the writing committee, external peer
reviewers, and participating organizations in the document, it
cannot respond to each issue raised after a document has been
published. The information, however, is forwarded to the Writing
Committee co-chairs and oversight Task Force for review. If any
issues are deemed by the College to affect patient safety, they will
be considered immediately. Otherwise, the information will be
considered during the next revision of the document.
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